Skip to main content

Table 3 Antifungal therapy (N = 412 patients)

From: Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes

Description VORI CASPO FLUC ITRA AMB POSA MICA ANID
Used drug at least once (%) 292 (70.87) 161 (39.08) 117 (28.40) 34 (8.25) 53 (12.86) 3 (0.73) 13 (3.16) 9 (2.18)
Used as initial monotherapy (%) (N = 354) 166 (46.89) 63 (17.80) 98 (27.68) 12 (3.39) 12 (3.39) 0 (0.00) 2 (0.56) 1 (0.28)
Used as initial combination therapy (%) (N = 58) 53 (91.38) 38 (65.51) 4 (6.90) 10 (12.50) 9 (11.25) 3 (5.08) 5 (8.62) 5 (8.62)
Length of initial therapy, days (SD) 12.1 (12.3) 9.1 (8.4) 6.0 (4.7) 8.4 (11.3) 7.3 (8.3) 14.3 (18.0) 7.7 (6.6) 10.6 (10.3)
 Length of initial therapy (Survivors) 12.8 (12.6) 10.9 (7.7) 6.7 (5.0) 9.4 (12.6) 7.1 (6.9) 14.3 (18.0) 8.7 (7.8) 11.3 (10.8)
 Length of initial therapy (Non-survivors) 11.2 (12.0) 7.2 (8.8) 6.4 (4.5) 6.1 (7.2) 7.4 (9.1) - 6.5 (5.2) 5.0 (−)
Mortality (% who received drug at least once) 125 (42.81) 79 (49.07) 66 (48.89) 10 (29.41) 33 (62.26) 0 (0.00) 6 (46.15) 1 (11.11)
Hospital admission to discharge, days (SD) 27.8 (26.3) 31.1 (31.1) 33.9 (24.2) 28.9 (19.5) 30.7 (25.2) 31.0 (21.2) 25.3 (17.0) 32.8 (20.7)
Drug initiation to discharge, days (SD) 19.2 (21.7) 21.0 (26.1) 25.1 (22.4) 21.7 (16.3) 23.2 (23.2) 24.0 (18.0) 20.5 (18.4) 26.3 (15.3)
  1. VORI, voriconazole; CASPO, caspofungin; FLUC, fluconazole; ITRA, itraconazole; POSA, posaconazole; MICA, micafungin; ANID, anidulafungin.
  2. SD=standard deviation.